Moving Beyond Amyloid in Alzheimer's Therapeutics

Alzheimer's Disease International. Dementia Statistics. Available from: https://www.alzint.org/about/dementia-facts-figures/ [Last accessed on: February 27, 2023].

Prados MJ , Liu Y , Jun H , et al. Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States. Alzheimers Dement, 2022; 18(1):142–151; doi: 10.1002/alz.12578.

AmyriAD webinar. Looking Beyond Amyloid for Alzheimer's Disease: Combination Therapy, a Strategy Long Overdue, Hosted by AmyriAD Therapeutics. Available from: https://lifesci.rampard.com/WebcastingAppv5/Events/conferences/customLanding.jsp?Y2lk=MjAwOA==[Last accessed on: February 27, 2023].

Rogers SL , Farlow MR , Doody RS , et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil study group. Neurology, 1998; 50(1):136–145; doi: 10.1212/wnl.50.1.136.

Burns A , Rossor M , Hecker J , et al. The effects of donepezil in Alzheimer's disease—Results from a multinational trial. Dement Geriatr Cogn Disord, 1999; 10(3):237–244; doi: 10.1159/000017126.

Mohs RC , Doody RS , Morris JC , et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 2001; 57(3):481–488; doi: 10.1212/wnl.57.3.481. Erratum in: Neurology 2001;57(3):1942.

Gauthier S , Rountree S , Finn B , et al. Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer's disease: A randomized phase 2 study. J Alzheimers Dis, 2015; 48(2):473–481; doi: 10.3233/JAD-150414.

Dos Santos Tramontin N , da Silva S , Arruda R , et al. Gold nanoparticles treatment reverses brain damage in Alzheimer's disease model. Mol Neurobiol, 2020; 57(2):926–936; doi: 10.1007/s12035-019-01780-w.

Matsumoto K , Funakoshi H , Takahashi H , et al. HGF/MET pathway in regeneration and drug discovery. Biomedicines, 2014; 2(4):275–300; doi: 10.3390/biomedicines2040275.

Hamasaki H , Honda H , Suzuki SO , et al. Down-regulation of MET in hippocampal neurons of Alzheimer's disease brains. Neuropathology, 2014; 34(3):284–290; doi: 10.1111/neup.12095.

Moebius HJ , Church KJ . The case for a novel therapeutic approach to dementia: Small molecule hepatocyte growth factor (HGF/MET) positive modulators. J Alzheimers Dis, 2023; 92(1):1–12; doi: 10.3233/JAD-220871.

O'Brian S , Packman A , Onslow M , et al. Generalizability theory II: Application to perceptual scaling of speech naturalness in adults who stutter. J Speech Lang Hear Res, 2003; 46(3):718–723; doi: 10.1044/1092-4388(2003/057).

Yang N , Kong B , Zhu Z , et al. Recent advances in targeted protein degraders as potential therapeutic agents. Mol Divers, 2023; 15:1–25; doi: 10.1007/s11030-023-10606-w. Epub ahead of print.

Tagai K , Ono M , Kubota M , et al. High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron, 2021; 109(1):42–58.e8; doi: 10.1016/j.neuron.2020.09.042.

Hsu JL , Lin KJ , Hsiao IT , et al. The imaging features and clinical associations of a novel tau PET tracer-18F-APN1607 in Alzheimer disease. Clin Nucl Med, 2020; 45(10):747–756; doi: 10.1097/RLU.0000000000003164.

Fang C , Hernandez P , Liow K , et al. Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer's and Parkinson's patients. J Prev Alzheimers Dis, 2023; 10(1):25–33; doi: 10.14283/jpad.2022.84